Correspondence 0001493152-23-043289 from Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc.
Date: Nov. 30, 2023 · CIK: 0001716166 · Accession: 0001493152-23-043289

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-275726

Date

Nov. 30, 2023

Author

Chief

Form

CORRESP

Company

Vivos Therapeutics, Inc.

Letter

VIA EDGAR Division of Corporation Finance Attention: Ben Richie Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-275726 Filed November 22, 2023

Dear Mr. Richie:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m. Eastern Time on Friday, December 1, 2023 (the “Effective Time”). The Company hereby grants to Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP the authority to communicate to the staff of the U.S. Securities and Exchange Commission one or more requests for any potential deferral of the Effective Time.

Very
truly yours,
/s/
R. Kirk Huntsman

Show Raw Text

CORRESP
1
filename1.htm

Vivos
therapeautics, Inc.

7921
Southpark Plaza, Suite 210

Littleton,
Colorado 80120

November
30, 2023

VIA
EDGAR

U.S.
SECURITIES AND EXCHANGE COMMISSION

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

Attention:
Ben Richie

    Re:
    Vivos
    Therapeutics, Inc.

    Registration
    Statement on Form S-1

    File
    No. 333-275726

    Filed
    November 22, 2023

Dear
Mr. Richie:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. (the “Company”) hereby requests
acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m. Eastern
Time on Friday, December 1, 2023 (the “Effective Time”). The Company hereby grants to Lawrence A. Rosenbloom,
Esq. of Ellenoff Grossman & Schole LLP the authority to communicate to the staff of the U.S. Securities and Exchange Commission one
or more requests for any potential deferral of the Effective Time.

    Very
    truly yours,

    /s/
    R. Kirk Huntsman

    R.
    Kirk Huntsman

    Chief
    Executive Officer

SecProbe.io